Matrine

Matrine (C₁₅H₂₄N₂O, MW 248.36 g/mol) is a quinolizidine alkaloid that exerts antitumor effects by inhibiting PI3K/AKT/mTOR signaling, suppressing NF-κB and MAPK inflammatory cascades, and modulating microRNA expression to downregulate oncogenic targets including EGFR, Bcl-2, and Wnt/β-catenin. In preclinical cell models, matrine reduced IL-6 to 82.14 ± 5.75% and TNF-α to 73.01 ± 1.56% of LPS-stimulated control levels in RAW 264.7 macrophages, while demonstrating concentration- and time-dependent proliferation inhibition across hepatoma, lung, and breast cancer cell lines.

Origin & History

Matrine is a tetracyclic quinolizidine alkaloid extracted predominantly from the roots of Sophora flavescens (Ku Shen), a flowering leguminous shrub native to China, Japan, Korea, and parts of Central Asia, where it grows in dry, rocky hillsides and open grasslands. Secondary botanical sources include Sophora alopecuroides and other Sophora species distributed across temperate Asia and the Mediterranean. The alkaloid was first isolated by the Japanese researcher Nagai in the late 19th century and has since been a cornerstone compound in traditional Chinese pharmacopeia preparations derived from dried Sophora roots.

Historical & Cultural Context

Sophora flavescens root (Ku Shen, meaning 'bitter ginseng') has been used in traditional Chinese medicine for over two millennia, documented in classical texts including the Shennong Bencao Jing (Divine Farmer's Materia Medica), where it was prescribed for conditions including dysentery, jaundice, skin inflammatory disorders, and parasitic infections. The alkaloid matrine was first chemically isolated by Japanese pharmacognosist Nagai in the late 19th century, representing one of the early phytochemical characterizations of Asian medicinal plant alkaloids. In Traditional Chinese Medicine, Ku Shen root decoctions were prepared by boiling dried root slices and administered orally or applied topically for eczema, leprosy-like skin conditions, and vaginal inflammatory conditions, reflecting the compound's recognized antimicrobial and anti-inflammatory properties. Matrine's modern pharmacological investigation expanded significantly from the 1980s onward, particularly in China, where it became a subject of intensive anticancer research and is incorporated into some registered Chinese proprietary medicines used in oncology supportive care.

Health Benefits

- **Anticancer Activity**: Matrine inhibits proliferation and induces apoptosis in hepatoma cells (HepG2, Huh7, Bel-7402) by suppressing PI3K/AKT/mTOR signaling, reducing stem cell markers CD90, CD133, and EpCAM, and lowering the Bcl-2/Bax ratio to favor programmed cell death.
- **Anti-inflammatory Effects**: By inhibiting NF-κB nuclear translocation and suppressing MAPK and JAK/STAT signaling cascades, matrine significantly reduces pro-inflammatory cytokine production, including decreasing IL-6 and TNF-α output in LPS-stimulated macrophages to approximately 82% and 73% of untreated model levels, respectively.
- **Cardiovascular Protection**: Matrine exerts cardioprotective effects by downregulating Akt phosphorylation at Thr495, upregulating endothelial nitric oxide synthase (eNOS) activity and GSK-3β phosphorylation, and reducing DDAH2 expression, collectively improving endothelial function and reducing oxidative vascular stress.
- **Antiviral and Antibacterial Properties**: Matrine demonstrates direct antimicrobial activity with minimum inhibitory concentrations of 12.5 mg/mL against Escherichia coli and 25 mg/mL against Staphylococcus aureus, while synthetic derivatives exhibit markedly enhanced potency, achieving 60–70% mosquito larvicidal activity at concentrations as low as 1 μg/mL.
- **Neuroprotective Effects**: Preclinical data indicate matrine attenuates neuroinflammatory cascades by suppressing glial NF-κB activation and reducing neurotoxic cytokine release, suggesting potential utility in inflammatory neurodegenerative conditions, though human evidence remains absent.
- **Antioxidant Activity**: Matrine scavenges reactive oxygen species and upregulates endogenous antioxidant pathways, partially through eNOS activation and GSK-3β modulation, reducing oxidative damage in cardiac and hepatic cell models.
- **Lung Cancer Suppression via miRNA Modulation**: In NCI-H1299 non-small cell lung cancer cells, matrine upregulates miR-133a expression, which subsequently inhibits the EGFR/AKT/MMP-9 axis, reducing both tumor cell proliferation and invasive metastatic potential in vitro.

How It Works

Matrine operates through pleiotropic molecular mechanisms centered on the suppression of oncogenic and inflammatory signaling networks. In hepatocellular carcinoma models, it inhibits the PI3K/AKT/mTOR pathway to reduce survival signaling, downregulates surface stem-cell markers (CD90, CD133, EpCAM, CCR7), and suppresses TMEM16A chloride channel expression while normalizing the Bcl-2/Bax apoptotic ratio. In breast cancer cells (MCF-7, T47D), matrine downregulates oncogenic miR-21 to derepress the tumor suppressor PTEN, leading to AKT dephosphorylation; it also suppresses LIN28A, allowing let-7b accumulation that in turn inhibits Wnt/β-catenin signaling and reduces cyclin D1 (CCND1) expression to arrest cell cycle progression. Anti-inflammatory activity is mediated through concurrent inhibition of NF-κB nuclear translocation, attenuation of p38 MAPK and ERK phosphorylation, and suppression of JAK2/STAT3 activation, reducing transcription of pro-inflammatory cytokine genes including IL-6, TNF-α, and IL-1β.

Scientific Research

The preponderance of matrine research consists of in vitro cell line studies and rodent in vivo models, with no published Phase I–III randomized controlled trials identified in the peer-reviewed literature to date. Preclinical evidence is mechanistically detailed and reproducible across multiple cancer cell lines, including hepatoma (HepG2, Huh7, Bel-7402), colorectal (RKO), lung (NCI-H1299), and breast (MCF-7, T47D) models, with quantified survival rates such as 86.6 ± 2.6% cell viability in Bel-7402 at tested concentrations, demonstrating concentration- and time-dependent antiproliferative effects. Anti-inflammatory studies in LPS-stimulated RAW 264.7 macrophages provide specific cytokine reduction data (IL-6: 82.14 ± 5.75%; TNF-α: 73.01 ± 1.56% of model group), lending reproducible quantitative benchmarks, though translation to human pharmacodynamics remains unvalidated. The overall evidence base is classified as preliminary-to-moderate in strength; while the mechanistic breadth and preclinical consistency are promising, the complete absence of registered human clinical trial data necessitates cautious interpretation of any therapeutic claims.

Clinical Summary

No human clinical trials with reported sample sizes, effect sizes, or controlled designs were identified for matrine as an isolated compound in the current literature. Matrine-containing traditional Chinese medicine formulations (e.g., Sophora flavescens root preparations) have historical use in clinical settings in China, particularly in oncology supportive care, but standardized outcome data from these applications are not consistently published in internationally indexed journals. Preclinical in vivo rodent studies support anti-inflammatory and antitumor activity, but species-specific pharmacokinetics, maximum tolerated doses in humans, and human bioavailability data have not been formally characterized in registerable trial formats. Confidence in matrine's clinical efficacy for any specific indication must therefore remain low until prospective, controlled human studies are completed.

Nutritional Profile

Matrine is a pure alkaloid compound (C₁₅H₂₄N₂O) and does not constitute a nutritional ingredient with macronutrient or micronutrient contributions. As a low-molecular-weight (248.36 g/mol) bicyclic nitrogen-containing organic compound, it belongs to the quinolizidine alkaloid class alongside structurally related compounds oxymatrine, sophoridine, and sophocarpine, which co-occur in Sophora flavescens root extracts. Bioavailability of matrine following oral administration is influenced by first-pass hepatic metabolism; preclinical rodent studies suggest moderate oral absorption, but human bioavailability data, plasma half-life, and protein binding parameters have not been formally established in published pharmacokinetic studies. The compound is soluble in water and common organic solvents, facilitating both aqueous traditional decoction extraction and modern organic solvent-based isolation techniques.

Preparation & Dosage

- **Pure Alkaloid Extract (Research Grade)**: Used in experimental concentrations ranging from 0.1–2.0 mg/mL in cell assays; no standardized human supplemental dose has been established from clinical trials.
- **Sophora flavescens Root Powder/Decoction (Traditional)**: Typically prepared as a water decoction of 3–9 g of dried root per day in traditional Chinese medicine practice, though matrine content varies significantly by extraction method and plant material quality.
- **Standardized Matrine Extract Capsules**: Available in some Asian herbal supplement markets at concentrations of 98% matrine purity, but no clinically validated dose range exists for human use; empirical traditional dosing is not directly translatable to isolated alkaloid doses.
- **Injectable Matrine Formulations**: Used in some Chinese clinical oncology settings as adjunctive therapy (e.g., matrine injection), with doses typically guided by institutional protocols rather than peer-reviewed trial consensus.
- **Timing Notes**: Animal studies administer matrine daily without specific circadian timing requirements; absence of human pharmacokinetic data precludes evidence-based timing recommendations.
- **Standardization Benchmark**: Research-grade extracts are standardized to ≥98% matrine by HPLC; commercial herbal products referencing Sophora flavescens extract are inconsistently standardized and may not declare matrine content.

Synergy & Pairings

Matrine's inhibition of the PI3K/AKT/mTOR pathway suggests potential additive or synergistic effects when combined with mTOR inhibitors (e.g., rapamycin analogues) or EGFR inhibitors used in oncology, as matrine simultaneously suppresses upstream receptor expression and downstream survival signaling through complementary nodes. In traditional Chinese medicine formulations, Sophora flavescens is frequently combined with Phellodendron amurense (Huang Bai) and Cnidium monnieri for enhanced antimicrobial and anti-inflammatory effects, a combination that may produce additive NF-κB suppression through distinct alkaloid classes acting on overlapping inflammatory pathways. Preclinical data also suggest that matrine's upregulation of PTEN and suppression of Wnt/β-catenin in breast cancer cells could be complemented by curcumin's independent downregulation of the same pathway, making a matrine-curcumin combination a theoretically rational but experimentally unvalidated anti-proliferative pairing.

Safety & Interactions

Matrine is characterized in preclinical literature as a relatively low-toxicity alkaloid with fewer adverse effects than crude Sophora flavescens whole-root extracts, though formal human toxicology studies establishing no-observed-adverse-effect levels (NOAELs) or maximum tolerated doses in humans are not available in the published literature. In animal models, high-dose matrine administration has been associated with neuromuscular effects consistent with nicotinic acetylcholine receptor modulation (a property shared by quinolizidine alkaloids as a class), suggesting potential for dose-dependent nervous system side effects at supratherapeutic concentrations. Potential drug interactions have not been systematically characterized in humans; based on its modulation of CYP enzyme substrates and PI3K/AKT pathway components, caution is theoretically warranted when co-administered with immunosuppressants, chemotherapeutic PI3K inhibitors, anticoagulants, or cardiovascular medications affecting nitric oxide signaling. Pregnancy and lactation safety data are absent, and given the compound's potent cell-cycle-modulating and cytokine-suppressing properties, use during pregnancy or breastfeeding should be strictly avoided pending evidence-based guidance.